Recruitment

Recruitment Status
Completed

Inclusion Criteria

No use of antibiotics in the preceding 6 months
No history of periodontal therapy in preceding last 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No use of antibiotics in the preceding 6 months
No history of periodontal therapy in preceding last 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm

Exclusion Criteria

Those on systemic ALN/bisphosphonate therapy
Immunocompromised subjects
Known or suspected allergy to the ALN/bisphosphonate group
...
Those on systemic ALN/bisphosphonate therapy
Immunocompromised subjects
Known or suspected allergy to the ALN/bisphosphonate group
Use of smokeless tobacco in any form,
Subjects with known systemic disease
Pregnant or lactating females
Alcoholics
Subjects with aggressive periodontitis,

Summary

Conditions
Chronic Periodontitis
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 30 years and 50 years
Gender
Both males and females

Inclusion Criteria

No use of antibiotics in the preceding 6 months
No history of periodontal therapy in preceding last 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No use of antibiotics in the preceding 6 months
No history of periodontal therapy in preceding last 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm

Exclusion Criteria

Those on systemic ALN/bisphosphonate therapy
Immunocompromised subjects
Known or suspected allergy to the ALN/bisphosphonate group
...
Those on systemic ALN/bisphosphonate therapy
Immunocompromised subjects
Known or suspected allergy to the ALN/bisphosphonate group
Use of smokeless tobacco in any form,
Subjects with known systemic disease
Pregnant or lactating females
Alcoholics
Subjects with aggressive periodontitis,

Tracking Information

NCT #
NCT02168543
Collaborators
Not Provided
Investigators
  • Principal Investigator: Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi
  • Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi